跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE
Approved
STANDARD
EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE
Astrazeneca Ab
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Mar 31, 2022
Approval ID
01446d1258f1d211
Company
Astrazeneca Ab
Type
Standard
Approval Details
Approval Id
01446d1258f1d211
Drug Cima Aemps Name
EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE
Register Number
1221651001
Holder Company Name
Astrazeneca Ab
Marketing Company Name
Astrazeneca Farmaceutica Spain S.A.
Holder Company Detail Path
/organization/astrazeneca-ab
Authorization Date
2022-03-31
Dosage Form
SOLUCIÓN INYECTABLE
Dose
150 MG+150 MG
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Diagnóstico Hospitalario
Commercialized
No
Company Name
Astrazeneca Ab
Company Detail Path
/organization/astrazeneca-ab
Company Information
Pharmaceutical Company Name
ASTRAZENECA AB
Country Name
Spain
City Name
madrid,madrid,country_es
Address
CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63
Website
http://www.astrazeneca.se
Active Ingredients
TIXAGEVIMAB
150 mg
CILGAVIMAB
150 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Mar 31, 2022
Approval ID
01446d1258f1d211
Type
Standard
Back to CIMA-AEMPS Approvals
